The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance
- PMID: 24018237
- DOI: 10.1016/j.juro.2013.08.088
The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance
Abstract
Purpose: Prostate biopsy related infectious complications are associated with significant morbidity. The risk of infectious complications in patients with prostate cancer on active surveillance remains under studied.
Materials and methods: A total of 591 consecutive men who underwent prostate biopsy were prospectively enrolled in a study evaluating prostate biopsy related complications between January 2011 and January 2012. Of these men 403 were previously diagnosed with prostate cancer and were included in this study. They underwent a 14-core transrectal ultrasound guided prostate biopsy as part of an active surveillance regimen. A nurse contacted all men within 14 days of biopsy, and information was collected on potential complications, antibiotics received and bacterial culture results.
Results: Fourteen patients (3.5%) had infectious complications including 13 requiring hospitalization. Five patients had positive urine cultures, and fluoroquinolone resistant isolates were identified in 4 patients, including 2 with extended spectrum beta-lactamase producing isolates. We evaluated the impact of risk factors including diabetes, benign prostatic hyperplasia and antibiotic regimen. However, only the number of previous prostate biopsies was significantly associated with an increased risk of infectious complications (p = 0.041). For every previous biopsy the odds of an infection increased 1.3 times (OR 1.33, 95% CI 1.01-1.74).
Conclusions: In men with prostate cancer on active surveillance the number of previous prostate biopsies is associated with a significant risk of infectious complications and every previous biopsy increases the risk of infectious complication. Fluoroquinolone resistant and extended spectrum beta-lactamase producing isolates represent the most commonly identified organisms. Men with prostate cancer on active surveillance should be informed of the risks associated with serial repeat prostate biopsies.
Keywords: biopsy; infection; prostatic neoplasms; sepsis; treatment outcome.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Prevalence of fluoroquinolone-resistant rectal flora in patients undergoing transrectal ultrasound-guided prostate needle biopsy: A prospective multicenter study.Int J Urol. 2018 Mar;25(3):278-283. doi: 10.1111/iju.13511. Epub 2017 Dec 14. Int J Urol. 2018. PMID: 29241300
-
Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization.Urol Oncol. 2018 Apr;36(4):158.e7-158.e12. doi: 10.1016/j.urolonc.2017.12.005. Epub 2017 Dec 26. Urol Oncol. 2018. PMID: 29288004
-
Comparison of Single and Prolonged Fluoroquinolone Prophylaxis and Risk Factors for Infectious Complications After Transrectal Prostate Biopsy.Balkan Med J. 2018 Sep 21;35(5):373-377. doi: 10.4274/balkanmedj.2018.0477. Epub 2018 Jun 5. Balkan Med J. 2018. PMID: 29866640 Free PMC article.
-
Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature.J Urol. 1998 Dec;160(6 Pt 1):2115-20. doi: 10.1097/00005392-199812010-00045. J Urol. 1998. PMID: 9817335 Review.
-
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.J Urol. 2001 Sep;166(3):856-60. J Urol. 2001. PMID: 11490233 Review.
Cited by
-
Optimizing safety and accuracy of prostate biopsy.Curr Opin Urol. 2016 Sep;26(5):472-80. doi: 10.1097/MOU.0000000000000310. Curr Opin Urol. 2016. PMID: 27214580 Free PMC article. Review.
-
Radiomics-Based Machine Learning Models for Predicting P504s/P63 Immunohistochemical Expression: A Noninvasive Diagnostic Tool for Prostate Cancer.Front Oncol. 2022 Jun 20;12:911426. doi: 10.3389/fonc.2022.911426. eCollection 2022. Front Oncol. 2022. PMID: 35795067 Free PMC article.
-
Variation in serum prostate-specific antigen levels in men with prostate cancer managed with active surveillance.BJU Int. 2016 Oct;118(4):535-40. doi: 10.1111/bju.13328. Epub 2015 Oct 26. BJU Int. 2016. PMID: 26385021 Free PMC article.
-
Evolution of a CDC Public Health Research Agenda for Low-Risk Prostate Cancer.Am J Prev Med. 2015 Dec;49(6 Suppl 5):S483-8. doi: 10.1016/j.amepre.2015.08.016. Am J Prev Med. 2015. PMID: 26590643 Free PMC article.
-
Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.Med Decis Making. 2019 Jul;39(5):499-508. doi: 10.1177/0272989X19861963. Epub 2019 Jul 18. Med Decis Making. 2019. PMID: 31319751 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical